RxDoctor Payments Data

Jose Martinez-Salas

Pulmonary Disease · Winter Haven, FLNPI 1396714838

Payments from drug & device makers

$11,666in general payments, 2019–2025

Across 18 payments — averaging $648.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • GSK$151
  • Abiomed$114
  • Alnylam Pharmaceuticals Inc.$97
  • Paratek Pharmaceuticals, Inc.$96
  • Actelion Pharmaceuticals US, Inc.$84
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,666 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$680,821
Medicare patients
576
Services billed
28,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter145$214,599
EliquisApixaban76$69,827
XolairOmalizumab13$46,608
Breo ElliptaFluticasone/Vilanterol47$38,131
SymbicortBudesonide/Formoterol Fumarate86$30,805
EntrestoSacubitril/Valsartan16$25,421
Arnuity ElliptaFluticasone Furoate52$23,899
Combivent RespimatIpratropium/Albuterol Sulfate27$23,761
XareltoRivaroxaban29$21,119
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$20,875
LinzessLinaclotide23$19,522
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$8,714
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$7,079
Albuterol Sulfate HfaAlbuterol Sulfate142$6,240
Azithromycin265$4,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$151$297,505265 claims
Johnson & JohnsonXarelto$20$21,11929 claims
AbbVieLinzess$11,037$19,52223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Winter Haven

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →